| 生物 | 为我校生物样本人工存储区购置超低温冰箱90台。 | 558 | 202 | | --- | --- | --- | --- | | 样本 | | | 5 | | 库人 | | | 年 | | 工存 | | | 7 | | 储系 | | | 月 | | 统购 | | | | | 置项 | | | | | 目 | | | | | 科技 | | | 202 | | 楼纯 | | | | | 水系 | | | 5 | | | 为我校科技楼购置1套纯水系统。 | 112 | 年 | | 统购 | | | 7 | | 置项 | | | 月 | | 目 | | | | | 医学 | | | 202 | | 科院 | | | | | | | | 5 | | 小型 | 为我校医学科学院购置荧光定量PCR仪，凝胶成像系统，梯度PCR | 100 | 年 | | 设备 | 仪、细胞计数器、低速冷冻离心机等小型设备。 | | 7 | | 购置 | | | 月 | | 项目 | | | | 导读： 近日，山西医科大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统 计出4项仪器设备采购意向，预算总额达1 ...

Core Viewpoint - The 18th China Scientific Instrument Development Annual Conference (ACCSI 2025) was held in Shanghai, where the "2024 Excellent New Products Award" in the scientific instrument industry was presented, recognizing 15 outstanding instruments [1][2]. Group 1: Event Overview - The award ceremony for the "3i Award - 2024 Excellent New Products in the Scientific Instrument Industry" took place during the ACCSI 2025, attended by over 1,700 industry professionals [2][6]. - The "Excellent New Products Award" aims to showcase innovative domestic and international instruments to Chinese users and encourage manufacturers to innovate [6][10]. Group 2: Award Selection Process - A total of 270 domestic and international manufacturers submitted 871 new instrument products for the award [7]. - After a rigorous evaluation process, 157 products were nominated, and ultimately, 15 instruments were awarded the 2024 Excellent New Products Award [7][10]. Group 3: Awarded Instruments - The awarded instruments include: - Agilent Technologies (China) Co., Ltd. - ProteoAnalyzer Parallel Capillary Protein Electrophoresis System - Thermo Fisher Scientific (China) Co., Ltd. - Thermo Scientific Iliad (Scanning) Transmission Electron Microscope - iQuad 2300P Directional Quantitative Microwave Sample-ICP Mass Spectrometer by Allhengsheng Mass Spectrometry (Beijing) Instrument Co., Ltd. - SURFSeq Q Ultra-High Throughput Gene Sequencing Instrument by Shenzhen Zhenmai Biotechnology Co., Ltd. - SE420 Flow Cytometry Sorting Instrument by Shanghai Weiran Technology Co., Ltd. [8][9].

Core Viewpoint - Suzhou Beikang Medical Co., Ltd. has reported a revenue growth of 43.8% in 2024, despite a sluggish market in the medical sector, indicating strong performance that exceeds sales expectations [1][3]. Revenue Growth and Product Development - The company specializes in third-generation IVF technology, particularly Preimplantation Genetic Testing (PGT), which enhances pregnancy success rates and reduces risks of genetic diseases [4]. - Beikang Medical has developed a comprehensive product line that includes reagents, consumables, instruments, and equipment for the assisted reproductive industry, providing a one-stop solution for medical institutions [4]. - The revenue has increased from RMB 107.3 million in 2021 to RMB 299.1 million in 2024, reflecting a compound annual growth rate of nearly 40% [5][4]. Financial Performance and Market Challenges - Despite revenue growth, the company has faced significant stock price declines, with a market capitalization drop of approximately 90% since its peak, now valued at around HKD 800 million [3][15]. - The company reported a net loss of RMB 237.2 million in 2024, a 23.1% increase in losses despite a revenue increase of over 40% [13][16]. - Sales costs have risen significantly, from RMB 116.6 million in 2023 to RMB 162.9 million in 2024, impacting profitability [16]. International Expansion and Market Potential - Beikang Medical has expanded its international presence, establishing a sales network covering over 30 countries and more than 1,000 medical institutions [11]. - The company has partnered with global fertility product suppliers, enhancing its international market reach [7]. - The assisted reproductive market in China has significant growth potential, with a current penetration rate of only 9.2%, compared to 36.0% in Europe and 33.0% in the U.S. [18].